Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07301255 · ClinicalTrials.gov registry record · Phase 2
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
A Phase 2 study of Asthma, sponsored by Enveda Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT07301255: Recruiting Phase 2 study of Asthma, sponsored by Enveda Therapeutics.
NCT07301255 is a Phase 2 study of Asthma that is actively recruiting participants, run by Enveda Therapeutics. The registered enrollment target is 50 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07301255, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Enveda Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Primary Outcome
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ENV-294
Study Locations (11)
California
- California Allergy and Asthma Medical - Los Angeles
- Allergy and Asthma Associates of Santa Clara Valley Research Center - San Jose
Oregon
- Portland Allergy & Asthma - Clackamas
- Velocity Clinical Research, Medford - Medford
Alabama
- AllerVie Clinical Research - Birmingham
Colorado
- Asthma and Allergy Associates - Colorado Springs
Georgia
- Georgia Pollens Clinical Research Centers - Albany
Kentucky
- Allergy & Asthma Specialists - Owensboro
Michigan
- Revive Research Institute - Southfield
Missouri
- The Clinical Research Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07301255 shows while recruiting
NCT07301255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07301255 lists 11 locations in 9 states (California, Oregon, Alabama).
Frequently Asked Questions
What is clinical trial NCT07301255 about?
NCT07301255 is a clinical study titled "ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults". This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants w...
What is the current status of trial NCT07301255?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-01-09. Estimated completion is 2027-01.
What conditions does trial NCT07301255 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07301255?
The interventions under investigation include: Placebo (DRUG), ENV-294 (DRUG).
Who is sponsoring clinical trial NCT07301255?
This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07301255 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07301255's enrollment target sits among peer trials
50 263rd of 374 higher than 106 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
-
Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI